InsiderTrades

Form 4 for TMP TOMPKINS FINANCIAL CORP

Accepted 2024-11-18 00:00:00 ET · period of report 2024-11-14 · accession 0001127602-24-027466 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2024-11-18 2024-11-14 TMP DeMilia David M EVP, Pres of TCB Hudson Valley F - Tax $74.67 -736 5,844 -11% -$55.0K
DM 2024-11-18 2024-11-14 TMP DeMilia David M EVP, Pres of TCB Hudson Valley M - OptEx $52.03 +875 6,277 +16% +$45.5K
DM 2024-11-18 2024-11-14 TMP DeMilia David M EVP, Pres of TCB Hudson Valley M - OptEx $0.00 -875 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-11-14 F D 303 $74.67 5,888.87 D — — (F1) Shares withheld for Option cost and taxes
2 Common Common Stock 2024-11-14 M A 348 $56.29 6,191.87 D — —
3 Common Common Stock 2024-11-14 M A 527 $49.22 6,276.87 D — —
4 Common Common Stock 2024-11-14 F D 433 $74.67 5,843.87 D — — (F1) Shares withheld for Option cost and taxes
5 Derivative Stock Appreciation Rights (SAR) 2024-11-14 M D 527 $0.00 0 D $49.22 · — to 2024-11-21 527 Common Stock (F2) Stock Appreciation Rights (SARs) were granted pursuant to the Tompkins Financial Corporation 2009 Equity Plan. SARs have a seven year vesting schedule with 0% vesting in year one, 17% vesting in years two through six, and 15% vesting in year seven. When exercised, the SARs will be settled in Common Stock of the Company. The grant will expire ten years from the date of the grant.
6 Derivative Stock Appreciation Rights (SAR) 2024-11-14 M D 348 $0.00 0 D $56.29 · — to 2025-11-04 348 Common Stock (F2) Stock Appreciation Rights (SARs) were granted pursuant to the Tompkins Financial Corporation 2009 Equity Plan. SARs have a seven year vesting schedule with 0% vesting in year one, 17% vesting in years two through six, and 15% vesting in year seven. When exercised, the SARs will be settled in Common Stock of the Company. The grant will expire ten years from the date of the grant.